A Phase I/II Study of Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) for the Treatment of Patients with Relapsed Multiple Myeloma
Stefano Sacchi(University of Modena and Reggio Emilia), Fortunato Morabito(Azienda Ospedaliera di Cosenza), Samantha Pozzi(University of Modena and Reggio Emilia), Roberto Ria(University of Bari Aldo Moro), Pellegrino Musto(University of Bari Aldo Moro), Stefania Badiali(University of Modena and Reggio Emilia), Antonio Lazzaro(Guglielmo da Saliceto Hospital), Attilio Guarini(Istituto Tumori Bari), Giovanni Quarta(Ospedale Papa Giovanni XXIII), Carla Mazzone, Antonio Palumbo(Azienda Ospedaliero Universitaria San Giovanni Battista), Donatella Vincelli(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Alessandro Corso(Aziende Socio Sanitarie Territoriale Ovest Milanese), Luciano Masini(Casa di Cura Villa Garda)
Cited by 2
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study
|Journal of Clinical Oncology|2007|374